human
parainfluenza
virus
hpiv
common
caus
sever
pediatr
respiratori
viral
diseas
character
wildtyp
infect
vitro
model
human
airway
epithelium
hae
found
viru
replic
high
titer
shed
apic
target
ciliat
cell
induc
minim
cytopatholog
replic
experiment
live
attenu
vaccin
strain
contain
temperatur
sensit
ts
nont
attenu
mutat
restrict
compar
hae
exhibit
littl
product
replic
restrict
parallel
attenu
upper
lower
respiratori
tract
african
green
monkey
support
hae
model
appropri
conveni
system
character
vaccin
candid
human
parainfluenza
viru
type
envelop
singlestrand
nonseg
negativesens
rna
viru
rubulaviru
genu
paramyxovirida
famili
similar
respiratori
syncyti
viru
rsv
influenza
viru
import
caus
sever
lower
respiratori
tract
diseas
includ
croup
bronchiol
pneumonia
children
less
year
old
hpiv
account
pediatr
hospit
respiratori
tract
diseas
alon
estim
respons
approxim
addit
caus
signific
morbid
infant
children
requir
medic
attent
hospit
licens
vaccin
current
avail
hpiv
despit
signific
impact
public
health
goal
develop
cdna
deriv
live
attenu
vaccin
safe
genet
stabl
protect
lower
respiratori
tract
diseas
young
children
live
attenu
vaccin
strategi
offer
sever
advantag
inactiv
subunit
formul
includ
abil
elicit
broadli
protect
immun
respons
consist
local
serum
antibodi
well
cell
respons
furthermor
live
attenu
vaccin
administ
intranas
replic
respiratori
tract
presenc
matern
antibodi
permit
immun
young
infant
caus
acut
selflimit
infect
readili
elimin
respiratori
tract
final
intranas
administr
live
attenu
viru
vaccin
induc
mucos
antigenspecif
immun
respons
upper
respiratori
tract
urt
major
impact
limit
replic
respiratori
virus
airway
sever
cdna
deriv
intranas
administ
live
attenu
viru
vaccin
evalu
clinic
trial
found
safe
immunogen
includ
licens
influenza
viru
vaccin
investig
vaccin
rsv
develop
vitro
vivo
test
identifi
live
attenu
respiratori
viru
vaccin
candid
exhibit
satisfactori
balanc
attenu
immunogen
human
need
extens
vivo
studi
often
perform
preclin
vaccin
develop
sinc
cell
line
gener
accur
reveal
level
attenu
viral
vaccin
candid
respiratori
tract
human
furthermor
restrict
host
rang
human
paramyxovirus
requir
use
nonhuman
primat
limit
expens
resourc
assess
level
attenu
therefor
avail
vitro
tissu
cultur
model
system
reflect
restrict
replic
attenu
human
respiratori
virus
nonhuman
primat
ultim
human
would
desir
preclin
develop
live
attenu
viru
vaccin
use
vitro
system
level
attenu
multipl
vaccin
candid
could
rapidli
assess
suitabl
vaccin
candid
could
select
evalu
nonhuman
primat
human
hpiv
rsv
replic
primarili
exclus
epitheli
cell
respiratori
tract
unless
individu
sever
immunocompromis
vitro
model
human
ciliat
airway
epithelium
hae
deriv
freshli
isol
human
airway
cell
grown
airliquid
interfac
shown
close
mimic
morpholog
physiolog
characterist
human
airway
epithelium
vivo
includ
mucociliari
transport
furthermor
hae
model
use
investig
characterist
viral
infect
number
respiratori
virus
includ
human
coronavirus
influenza
virus
rsv
although
virus
infect
ciliat
cell
model
consequ
infect
vari
exampl
infect
influenza
virus
caus
extens
earli
cytopatholog
hae
wherea
rsv
caus
overt
earli
cytopatholog
ciliat
cell
tropism
virus
critic
role
ciliat
cell
innat
airway
defens
suggest
central
role
ciliat
cell
viru
replic
spread
like
advers
consequ
function
epithelium
respiratori
tract
propos
hae
cultur
model
may
use
assess
restrict
replic
vitro
parallel
restrict
replic
attenu
ill
human
host
chosen
test
util
hae
estim
level
attenu
live
attenu
cdna
deriv
vaccin
candid
design
vaccin
candid
administ
upper
lower
respiratori
tract
african
green
monkey
agm
current
phase
clinic
trial
design
contain
three
attenu
element
c
substitut
nucleotid
genom
promot
tc
substitut
viral
polymeras
l
delet
polymeras
l
tc
mutat
origin
identifi
spontan
mutat
follow
vitro
passag
wildtyp
wt
cell
mutat
nontemperatur
sensit
nont
effici
attenu
viru
upper
urt
lower
lrt
respiratori
tract
agm
well
lrt
hamster
l
mutat
origin
identifi
ts
attenu
mutat
l
polymeras
vaccin
candid
stabil
mutant
l
sequenc
enhanc
genet
engin
codon
assign
would
requir
three
nucleotid
chang
revert
origin
wildtyp
tyrosin
amino
acid
assign
substitut
mutat
result
ts
att
phenotyp
restrict
replic
observ
lrt
agm
hamster
lastli
delet
codon
l
l
increas
level
temperatur
sensit
attenu
bear
tc
l
mutat
confer
stabl
attenu
phenotyp
point
mutat
deriv
l
att
point
mutat
bovin
vaccin
candid
viru
contain
mutat
found
ts
vitro
replic
shutoff
temperatur
manifest
restrict
replic
urt
lrt
agm
mean
peak
titer
reduc
urt
lrt
infect
agm
compar
induc
moder
rise
hemagglutinationinhibit
hai
antibodi
agm
immun
protect
agm
wildtyp
challeng
utr
lrt
present
studi
util
hae
cultur
first
character
infect
human
ciliat
airway
epithelium
respect
level
durat
replic
cell
tropism
polar
infect
cytopatholog
cellular
respons
infect
data
demonstr
infect
ciliat
cell
viru
releas
apic
surfac
product
replic
take
place
absenc
earli
gross
morpholog
chang
epithelium
effici
replic
hae
allow
us
compar
level
restrict
replic
hae
previous
observ
agm
restrict
replic
versu
hae
correl
close
seen
urt
lrt
respect
agm
ongo
clinic
trial
provid
vaccin
viru
replic
data
seroneg
children
need
assess
util
hae
system
identifi
live
vaccin
virus
appropri
attenu
human
airway
tracheobronchi
epitheli
cell
isol
airway
specimen
patient
without
underli
lung
diseas
tissu
provid
nation
diseas
research
interchang
ndri
philadelphia
pa
unc
cystic
fibrosi
center
tissu
cultur
core
excess
tissu
follow
lung
transplant
accord
protocol
approv
institut
review
board
univers
north
carolina
chapel
hill
primari
cell
deriv
singl
patient
sourc
first
expand
plastic
plate
collagenco
permeabl
transwellcol
diamet
support
densiti
cell
per
well
hae
cultur
grown
custom
media
provis
airliquid
interfac
ali
week
form
differenti
polar
cultur
resembl
vivo
pseudostratifi
mucociliari
epithelium
previous
describ
rhesu
monkey
cell
atcc
ccl
human
cell
atcc
ccl
maintain
optimem
gibcoinvitrogen
inc
grand
island
ny
supplement
fb
gentamicin
sulfat
recombin
describ
base
biologicallyderiv
strain
isol
nasal
wash
specimen
infect
infant
kindli
provid
dr
peter
wright
vanderbilt
univers
sequenc
strain
determin
previous
genbank
access
viru
deriv
antigenom
cdna
copi
genom
genom
vaccin
viru
engin
describ
previous
refer
previou
public
contain
three
attenu
element
mutat
nucleotid
tc
genom
promot
substitut
l
l
six
nucleotid
delet
l
l
deriv
strain
media
use
propag
cell
contain
trypleselect
recombin
trypsinlik
proteas
gibcoinvitrogen
inc
activ
f
protein
purifi
viru
stock
obtain
infect
cell
purifi
viru
cell
cultur
supernat
centrifug
band
discontinu
wv
sucros
gradient
order
minim
contamin
cellular
factor
viru
titer
determin
serial
dilut
cell
plate
day
co
infect
detect
hemadsorpt
guinea
pig
erythrocyt
viral
titer
express
tissu
cultur
infecti
dose
per
ml
log
tcid
ml
apic
surfac
hae
cultur
wash
phosphatebuff
salin
pb
limit
effect
apic
secret
inocula
fresh
media
suppli
basolater
compart
prior
inocul
hpiv
virus
dilut
cultur
medium
appli
either
apic
basolater
surfac
hae
moi
tcid
cell
tcid
cell
inoculum
incub
two
hour
either
inoculum
remov
cell
wash
three
time
min
pb
incub
viru
releas
apic
compart
harvest
perform
apic
wash
media
min
basolater
sampl
collect
directli
basolater
compart
remov
volum
replac
fresh
media
sampl
collect
hour
postinocul
store
analysi
confluent
monolay
cultur
cell
plate
infect
triplic
moi
tcid
cell
incub
one
hour
viru
cultur
wash
three
time
incub
indic
medium
well
harvest
replac
fresh
medium
h
interv
store
analysi
viru
present
sampl
quantifi
titrat
cell
detect
hemadsorpt
hae
fix
overnight
methanol
aceton
permeabil
triton
fix
cell
block
bovin
serum
albumin
bsa
pb
contain
cacl
mgcl
prior
incub
apic
surfac
antibodi
dilut
bsa
cell
detect
use
antibodi
obtain
fluid
present
subcutan
chamber
rabbit
immun
purifi
dilut
neutral
antibodi
titer
describ
previous
follow
addit
fluorescein
isothiocyan
fitc
conjug
goat
antirabbit
igg
dilut
jackson
immunoresearch
laboratori
inc
west
grove
pa
cell
detect
use
rabbit
antibodi
describ
previous
imag
acquir
use
leica
dmird
invert
fluoresc
microscop
equip
cool
color
chargecoupl
devic
digit
camera
micropublish
qimag
burnabi
british
columbia
canada
percentag
epithelium
posit
viral
antigen
index
percentag
infect
cell
quantifi
imag
per
cultur
black
white
pixil
imag
comput
calcul
percent
black
pixel
invert
imag
techniqu
determin
percentag
black
pixel
defin
area
account
differ
fluoresc
intens
hae
fix
methanol
aceton
embed
paraffin
prepar
histolog
section
section
stain
hematoxylin
eosin
h
e
alcian
bluepa
analysi
light
microscopi
subject
standard
immunofluoresc
protocol
immunofluoresc
section
block
bsa
pb
incub
primari
antibodi
rabbit
antibodi
mous
antiacetyl
alpha
tubulin
zyme
san
francisco
ca
dilut
bsa
primari
antibodi
detect
fitcconjug
goat
antirabbit
igg
rhodamin
redconjug
goat
antimous
jackson
immunoresearch
laboratori
inc
dilut
wash
cell
overlaid
fluorsav
mount
medium
emd
chemic
inc
amount
type
ifn
produc
viru
infect
hae
determin
previous
describ
ifn
bioassay
method
briefli
apic
wash
sampl
ph
inactiv
viru
acidlabil
type
ii
ifn
serial
dilut
cell
alongsid
human
standard
pgml
avonex
biogen
inc
cambridg
h
cell
infect
recombin
vesicular
stomat
viru
vsvgfp
obtain
john
hiscott
gfp
express
measur
use
typhoon
scanner
molecular
dynam
inc
sunnyval
ca
dilut
number
gfpposit
cell
approxim
untreat
well
consid
end
point
compar
end
point
standard
calcul
concentr
type
ifn
sampl
cellular
toxic
due
infect
determin
measur
amount
adenyl
kinas
ak
leakag
apic
compart
hae
ak
intracellular
enzym
releas
cell
cell
membran
disrupt
previous
shown
correl
proport
dead
damag
cell
viru
infect
measur
cytotox
hae
aliquot
apic
wash
sampl
collect
time
point
centrifug
immedi
collect
elimin
cell
debri
prior
freez
sampl
supernat
ak
concentr
determin
apic
wash
supernat
sampl
use
toxilight
bioassay
kit
lonza
rockland
inc
rockland
accord
manufactur
direct
ak
activ
upon
reaction
toxilight
reagent
detect
use
luminesc
micropl
reader
softmax
pro
softwar
molecular
devic
sunnyval
ca
studi
seroneg
african
green
monkey
agm
previous
report
agm
infect
agm
infect
histor
data
combin
data
addit
agm
studi
yield
larger
group
accur
comparison
agm
inocul
intranas
intratrach
tcid
recombin
site
nasopharyng
swab
tracheal
lavag
sampl
collect
day
describ
previous
viru
titer
sampl
determin
serial
dilut
monolay
describ
lower
limit
detect
log
tcid
ml
wildtyp
infect
vitro
model
human
ciliat
airway
epithelium
hae
first
character
hae
inocul
apic
surfac
high
moi
tcid
cell
apic
basolater
compart
assess
progeni
viru
releas
time
quantif
viru
apic
compart
provid
evid
rapid
robust
replic
apic
shed
progeni
hae
titer
increas
within
first
hour
follow
apic
inocul
reach
peak
titer
approxim
tcid
ml
apic
wash
sampl
day
pi
postinocul
fig
indic
abl
product
infect
hae
contrast
high
level
viru
detect
apic
wash
littl
viru
measur
limit
detect
basolater
compart
time
point
fig
growth
kinet
measur
viru
releas
apic
compart
correl
well
number
cell
stain
posit
viral
antigen
en
face
immunostain
antigen
fig
b
c
day
pi
viral
antigen
detect
cell
dispers
across
surfac
hae
howev
despit
high
moi
inocul
averag
surfac
epitheli
cell
posit
viral
antigen
indic
minor
hae
cell
infect
initi
inoculum
sinc
appear
infect
primarili
ciliat
cell
hae
fig
cell
given
hae
cultur
ciliat
cell
type
estim
ciliat
cell
cultur
infect
inocul
infect
hae
produc
maximum
titer
day
pi
demonstr
high
level
viru
detect
apic
compart
proport
cell
posit
antigen
time
point
number
infect
cell
declin
day
reach
peak
day
pi
fig
declin
number
infect
cell
correl
reduct
viral
titer
determin
day
pi
still
signific
number
cell
stain
posit
day
pi
viral
shed
detect
apic
compart
final
day
sampl
although
apic
inocul
hae
result
basolater
shed
viru
infect
hae
via
basolater
compart
possibl
result
increas
apic
titer
indic
rout
infect
product
fig
follow
basolater
inocul
hae
moi
tcid
cell
viru
could
detect
apic
compart
titer
rang
tcid
ml
day
pi
confirm
inde
abl
infect
hae
follow
basolater
exposur
repeat
experi
lower
moi
tcid
cell
observ
infect
hae
apic
basolater
evidenc
detect
increas
viru
titer
apic
wash
sampl
fig
howev
viru
titer
basolater
compart
increas
cours
infect
appear
shed
primarili
apic
surfac
regardless
inocul
rout
fig
addit
cultur
inocul
either
apic
basolater
parallel
comparison
upon
apic
inocul
robust
shed
apic
surfac
detect
indic
product
infect
hae
fig
previous
report
viru
shed
basolater
compart
observ
follow
basolater
inocul
viru
detect
earli
time
point
day
pi
basolater
wash
sampl
declin
titer
viru
period
suggest
viru
detect
repres
residu
inoculum
evid
replic
within
hae
contrast
result
viru
shed
detect
apic
compart
basolater
infect
hae
therefor
infect
hae
apic
basolater
inocul
observ
infect
cultur
deriv
four
differ
donor
via
basolater
surfac
contrast
abl
infect
cultur
basolater
inocul
indic
capabl
enter
hae
via
apic
basolater
surfac
en
face
immunostain
antigen
verifi
cell
hae
infect
via
apic
basolater
inocul
via
basolater
inocul
fig
level
replic
compar
cell
hae
determin
hae
abl
detect
attenu
phenotyp
detect
cell
growth
cell
resembl
fig
wherea
hae
lower
fig
indic
hae
detect
nont
att
phenotyp
appar
cell
restrict
replic
compar
much
pronounc
hae
cell
fig
moder
restrict
replic
cell
compat
presenc
ts
att
mutat
vaccin
viru
clearli
greater
restrict
replic
hae
indic
hae
sensit
two
system
detect
attenu
mutat
regard
viru
shed
basolater
surfac
follow
apic
inocul
behav
like
ie
shed
either
temperatur
data
shown
epitheli
cell
line
airway
secret
cytokin
chemokin
contribut
inflammatori
patholog
well
protect
immun
respons
previous
demonstr
infect
hae
induc
signific
level
type
interferon
ifn
secret
infect
mutant
encod
defect
ifn
antagonist
c
protein
induc
high
level
ifn
previou
studi
induct
ifn
correl
restrict
replic
mutant
hae
model
present
studi
compar
concentr
type
ifn
apic
compart
follow
infect
determin
whether
ifn
play
role
restrict
replic
either
viru
type
ifn
bare
pgml
ifn
detect
day
lower
limit
detect
pgml
detect
apic
compart
cultur
maintain
either
six
day
studi
observ
impli
strong
inhibit
ifn
induct
oper
wt
mutant
support
data
cell
line
infect
find
indic
attenu
hae
mediat
mutat
directli
involv
ifn
product
restrict
replic
specifi
attenu
mutat
might
contribut
weak
ifn
respons
determin
cell
type
target
character
effect
infect
airway
epitheli
cell
morpholog
histolog
cross
section
hae
stain
acetyl
alphatubulin
marker
ciliat
cell
viral
antigen
detect
throughout
cytoplasm
cell
also
stain
posit
acetyl
alphatubulin
indic
ciliat
cell
infect
although
everi
ciliat
cell
infect
even
late
time
point
fig
ciliat
cell
also
infect
follow
basolater
inocul
data
shown
similar
also
target
ciliat
cell
hae
fig
morpholog
assess
histolog
cross
section
reveal
infect
induc
gross
chang
morpholog
integr
epithelium
compar
mockinocul
cultur
fig
section
hae
fix
final
day
sampl
day
show
neither
infect
associ
overt
cytotox
syncytia
format
addit
mucociliari
function
determin
visual
inspect
ciliari
motion
infect
hae
use
light
microscop
time
point
appear
significantli
compromis
infect
alcian
bluepa
stain
reveal
slightli
increas
mucin
product
hour
pi
virusinfect
cultur
compar
mockinocul
cultur
data
shown
next
evalu
whether
infect
induc
cytotox
hae
undetect
gross
morpholog
analysi
cytotox
evalu
quantif
plasma
membran
damag
result
releas
cytoplasm
content
extracellular
space
ie
surround
fluid
ubiquit
cellular
protein
rapidli
releas
cultur
medium
result
plasma
membran
damag
adenyl
kinas
ak
measur
ak
activ
apic
wash
sampl
use
determin
viru
titer
possibl
correl
amount
progeni
viru
releas
level
cytotox
particular
cultur
infect
hae
cultur
maintain
either
fig
c
respect
ak
releas
peak
day
pi
follow
peak
level
ongo
viral
replic
correl
lower
viru
titer
time
point
howev
infect
either
temperatur
induc
minim
ak
releas
fig
b
substanti
less
associ
infect
indic
least
increas
viru
replic
correl
increas
ak
releas
signific
ak
releas
detect
mockinfect
cultur
handl
ident
data
shown
rel
transient
increas
ak
releas
hae
associ
signific
alter
morpholog
epithelium
cultur
figur
data
shown
order
determin
whether
attenu
hae
model
correl
att
phenotyp
agm
compar
viru
titer
apic
wash
hae
respiratori
secret
agm
either
viru
mean
viru
titer
day
apic
wash
hae
incub
approxim
higher
mean
peak
titer
urt
upper
respiratori
tract
nasopharyng
swab
agm
fig
differ
approxim
hae
lrt
lower
respiratori
tract
tracheal
lavag
fluid
agm
fig
restrict
replic
versu
log
urt
agm
p
log
hae
cultur
p
wherea
log
lrt
agm
p
log
hae
p
indic
good
correl
two
system
either
temperatur
focu
studi
character
infect
vitro
model
hae
assess
util
model
evalu
phenotyp
candid
live
attenu
viru
vaccin
although
anim
model
given
import
clue
level
attenu
potenti
vaccin
strain
sought
establish
human
tissu
cultur
system
reflect
attenu
respiratori
viru
vaccin
candid
seroneg
human
toward
goal
compar
replic
vaccin
candid
current
clinic
trial
wt
viru
hae
evalu
sever
factor
affect
viral
pathogenesi
respiratori
epithelium
includ
cytotox
target
cell
type
polar
viru
releas
abil
virus
induc
ifn
respons
concept
hae
may
use
tool
correl
vitro
attenu
vivo
attenu
support
studi
attenu
mutat
sever
respiratori
virus
includ
influenza
b
virus
rsv
exhibit
reduc
growth
hae
compar
parent
strain
furthermor
data
studi
demonstr
correl
attenu
hae
attenu
anim
model
seroneg
children
specif
level
attenu
two
vaccin
candid
exhibit
differ
level
attenu
agm
accur
reflect
hae
indic
potenti
evalu
respiratori
viru
vaccin
candid
model
studi
evalu
attenu
investig
rsv
vaccin
also
found
good
correl
growth
hae
chimpanze
seroneg
children
current
studi
comparison
restrict
replic
hae
level
close
mirror
attenu
vivo
agm
mean
peak
titer
urt
agm
hae
restrict
replic
hae
observ
nonpolar
cell
line
replic
equival
permiss
temperatur
thu
contain
host
rang
attenu
mutat
specifi
attenu
ie
restrict
replic
agm
hae
cell
suggest
restrict
replic
permiss
temperatur
hae
due
tc
mutat
genom
promot
shown
previous
nont
mutat
specifi
attenu
urt
lrt
agm
hae
lrt
agm
replic
highli
attenu
approxim
lower
titer
like
due
addit
effect
nont
ts
attenu
mutat
correl
extent
vaccin
attenu
hae
agm
strengthen
concept
hae
model
use
determin
attenu
phenotyp
potenti
respiratori
viru
vaccin
candid
recent
data
vdelet
mutant
ko
also
show
attenu
vivo
may
reflect
hae
mutant
unabl
grow
detect
level
either
hae
agm
howev
clear
demonstr
quantit
correl
attenu
vivo
hae
requir
extens
test
panel
virus
vari
level
attenu
system
safeti
level
replic
immunogen
determin
seroneg
children
level
sensit
agm
hae
model
identifi
satisfactori
level
attenu
human
known
underattenu
seroneg
infant
virus
attenu
compar
studi
hae
andor
agm
select
evalu
human
find
ciliat
cell
hae
permiss
infect
consist
sever
respiratori
virus
includ
influenza
viru
sarscov
rsv
although
infect
hae
less
robust
hae
clearli
support
replic
amplif
viru
titer
therefor
use
model
characterist
infect
human
respiratori
tract
vivo
level
replic
hae
correl
seen
human
cell
line
may
reflect
lower
incid
sever
diseas
associ
viru
versu
hpiv
abil
infect
hae
replic
peak
titer
approxim
tcid
ml
suggest
viru
product
infect
upper
respiratori
tract
human
therebi
trigger
adapt
immun
respons
vaccine
addit
restrict
replic
observ
declin
viru
titer
day
onward
indic
even
absenc
immun
cell
humor
immun
respons
viru
replic
restrict
innat
epitheli
immun
system
initi
suspect
decreas
viru
shed
might
due
product
cytokin
immun
mediat
epitheli
cell
suppress
viru
growth
previou
studi
mutant
possess
mutat
disabl
viral
ifn
antagonist
gene
indic
type
ifn
secret
hae
cell
capabl
reduc
replic
virus
render
suscept
antivir
effect
ifn
howev
evalu
type
ifn
respons
show
link
ifn
product
hae
reduct
replic
though
rule
contribut
innat
epitheli
cell
respons
limit
viru
replic
surpris
sinc
poss
mutat
v
protein
known
ifn
antagonist
gene
rather
failur
detect
ifn
cultur
infect
cell
reflect
restrict
replic
viru
impos
mutat
l
genom
promot
futur
studi
hae
like
understand
innat
immun
respons
airway
epitheli
cell
limit
extent
durat
respiratori
viru
infect
mechan
host
rang
mutat
tc
mutat
restrict
replic
human
ciliat
epitheli
cell
addit
cytokin
product
vivo
infect
respiratori
virus
caus
dramat
chang
respiratori
epithelium
exampl
influenza
viru
infect
result
dramat
cytopath
effect
columnar
cell
hae
cultur
within
hour
earli
cessat
cilial
beat
eventu
loss
columnar
epitheli
cell
although
basal
epitheli
cell
spare
contrast
cytopatholog
induc
hae
rsv
infect
much
subtl
induc
influenza
virus
similarli
infect
hae
induc
syncytia
format
disrupt
overal
mucociliari
function
epitheli
integr
dramat
alter
compar
uninfect
cultur
donor
howev
observ
may
due
partli
low
number
cell
infect
cultur
cytotox
assay
detect
alter
hae
observ
histolog
analys
cytotox
could
due
either
death
infect
cell
cytopath
effect
viral
infect
cellular
apoptot
mechan
contrast
exhibit
minim
cytotox
determin
ak
releas
correspond
lower
level
replic
polar
hae
model
apic
compart
repres
airway
lumen
basolater
compart
repres
interstiti
vascular
support
lung
hpiv
vaccin
develop
intranas
inocul
vaccin
strain
must
abl
product
infect
apic
lumin
cell
surfac
intranas
administr
studi
confirm
inocul
apic
surfac
hae
product
rout
infect
support
intranas
inocul
mean
vaccin
interestingli
also
appear
abl
enter
hae
via
basolater
surfac
paramyxovirus
measl
viru
genu
morbilliviru
also
enter
hae
via
basolater
surfac
yet
like
measl
viru
releas
primarili
apic
whether
abil
infect
hae
basolater
inocul
biolog
signific
unknown
indic
viremia
report
sign
system
ill
fever
seen
immunocompet
individu
significantli
follow
inocul
viru
shed
appear
primarili
apic
side
polar
hae
cultur
vivo
would
result
shed
lumen
away
underli
tissu
increas
likelihood
infect
remain
local
epitheli
surfac
respiratori
tract
although
apic
bud
mechan
restrict
system
spread
viru
similar
restrict
viru
releas
apic
surfac
also
seen
previous
relat
parainfluenza
virus
well
rsv
influenza
viru
consist
pattern
infect
limit
respiratori
tract
typic
seen
throughout
cours
diseas
human
infect
clinic
data
also
indic
wt
shed
lumen
present
respiratori
secret
wherea
viremia
replic
distant
site
report
similarli
viremia
detect
spite
high
titer
replic
urt
lrt
agm
unpublish
data
asn
ac
brm
observ
releas
apic
surfac
import
vaccin
develop
unlik
caus
viremia
spread
system
organ
vaccine
summari
investig
vaccin
character
extens
hae
agm
highli
attenu
studi
extend
analysi
human
vitro
model
system
like
predict
hpiv
replic
airway
seroneg
children
demonstr
consist
high
level
attenu
human
ciliat
epitheli
cell
indic
unlik
caus
sever
lower
respiratori
diseas
seroneg
children
close
correl
limit
growth
versu
agm
hae
provid
addit
evid
viru
attenu
human
sinc
current
evalu
clinic
trial
live
attenu
vaccin
candid
valuabl
compar
data
gener
hae
model
level
replic
seroneg
human
order
fulli
assess
correl
level
attenu
vaccin
candid
hae
model
versu
human
clinic
trial
indic
addit
vaccin
candid
need
develop
hae
use
togeth
assess
candid
favor
attenu
profil
clinic
develop
cytotox
quantifi
measur
adenyl
kinas
activ
apic
wash
sampl
circl
scale
left
yaxi
adenyl
kinas
sampl
activ
bioluminesc
detect
reagent
toxilight
bioassay
kit
detect
use
luminomet
activ
express
rel
luminesc
unit
rlu
viru
titer
apic
sampl
shown
dash
line
refer
use
scale
figur
scale
right
yaxi
agm
apic
wash
hae
incub
graph
peak
viru
titer
irrespect
sampl
day
agm
indic
circl
infect
agm
squar
infect
agm
viru
titer
hae
determin
high
moi
growth
curv
fig
titer
shown
apic
wash
sampl
collect
day
pi
line
indic
mean
peak
titer
group
se
singl
asterisk
indic
statist
signific
p
valu
indic
p
valu
twoway
anova
bonferroni
posttest
